化学
基诺美
变构调节
细胞生物学
药物发现
生物化学
激酶
生物
酶
作者
Alex G. Baldwin,David Foley,Dyfyr Heulyn Jones,Hyun-Ah Lee,Ross J. Collins,Ben Wahab,Josephine H. Pedder,Loren Waters,Marie Paine,Lauramariú Schino,Gui Jie Feng,Benson M. Kariuki,Jonathan M. Elkins,John R. Atack,Simon E. Ward
标识
DOI:10.1021/acs.jmedchem.5c00974
摘要
Abstract LIMKs are serine/threonine and tyrosine kinases that play critical roles in regulating actin filament turnover, affecting key cellular processes such as cytoskeletal remodeling, proliferation and migration. Aberrant LIMK overactivation has been implicated in several diseases, including cancers and neurodegenerative disorders. Understanding the precise molecular mechanisms by which LIMKs modulate actin cytoskeletal dynamics necessitates highly potent and selective LIMK pharmacological inhibitors. We report the discovery of a novel class of allosteric dual-LIMK1/2 inhibitors based on the tetrahydropyrazolopyridinone scaffold. Using structure-based drug design, we identified MDI-117740 (69) as a highly potent dual-LIMK1/2 inhibitor with significantly improved DMPK properties compared to prior inhibitors, suitable for in vivo evaluation. Importantly, 69 has very low kinome promiscuity, including former off-target RIPK1, representing the most selective LIMK inhibitor reported to date. Such a chemical probe will enable researchers to selectively dissect LIMK activation under physiological or disease conditions and spur translation of new therapeutics targeting LIMK pathologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI